Blog >
Welcoming New Member Holger Mueller

Blog

Welcoming New Member Holger Mueller

Umbrex is pleased to welcome Holger Bernd Mueller with Tmmune AG.  Holger built his career on the two pillars of strategy consulting and commercialization of innovations in the pharmaceutical industry. After his forming education at Bain & Company, Holger joined Novartis Pharma in headquarter- and country-organization roles, covering the entire lifecycle of a pharmaceutical drug from first-in-man trials to loss-of-exclusivity transitions. Following his career at Novartis, Holger ventured into the world of start-ups, where he held commercial leadership positions at the cell therapy company Athenex, the CRO Biognosys, and the medical device start-up Spiden.

Today, Holger works as an independent advisor to innovative pharmaceutical companies and holds non-executive director roles. His core expertise is in positioning- and commercialization of pharmaceutical drugs in the European markets, where he is agnostic to the therapeutic area.